Please answer the below questions after reading the attached case study:

AH Biotech Dr. Abra ham Hassan knew that he couldn't put off the decision any longer. AH Biotech, the Bound Brook, New Jerseybased company started by this psychiatristturned entrepreneur, had developed a novel drug that seemed to promise long-term relief from panic attacks. If it gained approval from the Food and Drug Administration {FDA}, it would be the company's rst product. It was now time for largescale clinical trials. But where should AH Biotech conduct those tests? David Berger, who headed up research and development, was certain he already knew the answer to that question: Albania. "Look, doing these trials in Albania will be quicker, easier, and a lot cheaper than doing them in the States,\" he pointed out. "What's not to like?\" Dr. Hassan had to concede that Berger's arguments were sound. If they did tn'als in the United States, AH Biotech would spend considerable time and money advertising for patients and then nding physicians who'd be willing to serve as clinical tn'al investigators. Rounding up US. doctors prepared to take on that job was getting increasingly difcult. They just didn't want to take time out of their busy practices to do the testing, not to mention all the recordkeeping that such a study entailed. In Albania, it was an entirely different story. It was one of the poorest Eastern European countriesif not the poorestwith a just barely functioning healthcare system. Albanian physicians and patients would practically line up at AH Biotech's doorstep begging to take part. Physicians there could earn much better money as clinical investigators for a US. company than they could aggajjypijagtjgigg medicine, and patients saw signing up as test subjects as their best chance for receiving any treatment at all, let alone cutting-edge 1v'tfesten'i medicine. All these factors meant that the company could count on realizing at least a 25 percent savings {maybe even more} by running the tests overseas. So, what's not to like? As the Egyptian-born lDEC! of a startup biotech company with investors and employees hoping for its rst marketable drug, there was absolutely nothing not to like. It was when he thought like a U.S. trained physician that he felt qualms. If he used US. test subjects, he knew they'd likely continue to receive the dmg until it was approved. At that point, most would have insurance that covered most of the cost of their prescriptions. But he already knew that it wasn't going to make any sense to market the drug in a poor country like Albania, so when the study was over, he'd have to cut off treatment. Sure, he conceded, panic attacks weren't usually fatal. But he knew how debilitating these sudden bouts of feeling completely terried werethe pounding heart, chest pain, choking sensation, and nausea. The severity and unpredictability of these attacks often made a normal life all but impossible. How could he offer people dramatic relief and then snatch it away